Maria Babak: Approval of axatilimab-csfr is a significant development in the treatment of cGVHD

Maria Babak shared a post by The Babak Lab on LinkedIn:

“This is a significant development in the treatment of chronic graft-versus-host disease (cGVHD). The FDA’s approval of axatilimab-csfr is backed by impressive trial results, offering a much-needed option for patients who haven’t responded to previous treatments.

If you’re in the healthcare field or have an interest in groundbreaking medical advancements, this is a must-read. Understanding these updates could be crucial for improving patient outcomes. Don’t miss out on this important information!”

Quoting The Babak Lab’s post:

“FDA Approves Axatilimab-csfr for Chronic Graft-Versus-Host Disease with Promising Trial Results

The FDA has just approved axatilimab-csfr (Niktimvo, Incyte) for treating chronic graft-versus-host disease (cGVHD) after the failure of two or more systemic therapies. This milestone is backed by the AGAVE-201 trial, which demonstrated a remarkable 75% overall response rate.

Key points:

• Indication: Treatment of cGVHD in patients (adults and pediatrics weighing at least 40 kg) after failure of two systemic therapies.
• Efficacy: Evaluated in the AGAVE-201 trial with a 75% overall response rate (ORR).
• Dosage: 0.3 mg/kg (max 35 mg) intravenous infusion every 2 weeks.
• Adverse Reactions: Common reactions include increased AST, infections, decreased phosphate, and more.

This represents a promising option for patients and healthcare providers dealing with challenging cGVHD cases. For more information, visit the FDA’s official site.”

Source: Maria Babak/LinkedIn and The Babak Lab/LinkedIn

Dr. Maria Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.

Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.